SCHEMBL4053057

SCHEMBL4053057

CCCOc1cccc(-c2nc3ncc(-c4ccccc4)cc3[nH]2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 4/20 0.50
MAPT P10636 4/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
NOS3 P29474 1/20 0.47
NOS1 P29475 1/20 0.47
NOS2 P35228 1/20 0.47
TBK1 Q9UHD2 1/20 0.46
TP53 P04637 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
USP2 O75604 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
RAB9A P51151 1/20 0.45
NFKB2 Q00653 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4053339 0.94 AURKA (0.50) AURKAMAPTNOS3NOS1NOS2
SCHEMBL4052666 0.92 PPARG (0.49) AURKANOS3NOS1NOS2TBK1
SCHEMBL4059595 0.90 TP53 (0.56) AURKAMAPTNOS3NOS1NOS2
SCHEMBL4059930 0.88 SCD (0.50) AURKAMAPTMEN1KMT2ATP53
SCHEMBL4229040 0.87 AURKA (0.47) AURKANOS3NOS1NOS2TBK1
SCHEMBL4055350 0.87 SMN1; SMN2 (0.53) AURKAMAPTMEN1KMT2ATP53
SCHEMBL4235517 0.87 AURKA (0.46) AURKANOS3NOS1NOS2TBK1
SCHEMBL4060694 0.87 AURKA (0.45) AURKAMAPTMEN1KMT2ANOS3
SCHEMBL4055330 0.86 AURKA (0.67) AURKANOS3NOS1NOS2TBK1
SCHEMBL4063060 0.85 DHODH (0.53) AURKANOS3NOS1NOS2TBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B AURKA 247/4885MAPT 4026/4885MEN1 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.